As of June 14, 2025, Apex Biotechnology Corp (1733.TW) reports a Gross Margin of 28.15%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Apex Biotechnology Corp's Gross Margin
Over recent years, Apex Biotechnology Corp's Gross Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2024-12-31 | 28.15% |
| 2023-12-31 | 31.68% |
| 2022-12-31 | 25.70% |
| 2021-12-31 | 26.81% |
| 2020-12-31 | 22.55% |
This slight downward trend highlights how Apex Biotechnology Corp manages its operational efficiency and pricing power over time.
Comparing Apex Biotechnology Corp's Gross Margin to Peers
To better understand Apex Biotechnology Corp's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Apex Biotechnology Corp (1733.TW) | 28.15% |
| Elbit Medical Technologies Ltd (EMTC.TA) | 9579.24% |
| Solborn Inc (035610.KQ) | 66.92% |
| Somnomed Ltd (SOM.AX) | 60.17% |
| Opto Circuits (India) Ltd (OPTOCIRCUI.NS) | 57.51% |
| MITech Co Ltd (179290.KQ) | 57.51% |
Compared to its competitors, Apex Biotechnology Corp's Gross Margin is among the lowest compared to peers, suggesting potential challenges in production costs or pricing strategy.